Los Angeles Capital Management
FATE icon

Los Angeles Capital Management’s Fate Therapeutics FATE Stock Holding History

Los Angeles Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$114K Hold
95,185
– – ﹤0.01% 1304
2025
Q4 		$123K Hold
95,185
– – ﹤0.01% 1365
2025
Q3 		$120K Buy
+95,185
New +$103K ﹤0.01% 1314
2023
Q1 		– Sell
-17,313
Closed -$175K – 1207
2022
Q4 		$175K Sell
17,313
-1,515
-8% -$28.5K ﹤0.01% 1149
2022
Q3 		$422K Buy
18,828
+1,247
+7% +$36K ﹤0.01% 970
2022
Q2 		$436K Buy
17,581
+601
+4% +$16.6K ﹤0.01% 1013
2022
Q1 		$658K Sell
16,980
-747
-4% -$28.9K ﹤0.01% 923
2021
Q4 		$1.04M Buy
17,727
+142
+0.8% +$8.05K ﹤0.01% 720
2021
Q3 		$1.04M Hold
17,585
– – ﹤0.01% 751
2021
Q2 		$1.53M Sell
17,585
-1,780
-9% -$143K 0.01% 673
2021
Q1 		$1.6M Sell
19,365
-11,433
-37% -$1.1M 0.01% 694
2020
Q4 		$2.8M Buy
30,798
+340
+1% +$21.1K 0.01% 554
2020
Q3 		$1.22M Buy
30,458
+1,375
+5% +$48K 0.01% 740
2020
Q2 		$998K Buy
29,083
+3,591
+14% +$107K ﹤0.01% 852
2020
Q1 		$566K Buy
+25,492
New +$645K ﹤0.01% 867

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Los Angeles Capital Management's FATE Position: Q1 2026 in Review

Los Angeles Capital Management held its Fate Therapeutics (FATE) position steady in Q1 2026 at 95,185 shares worth $114K. The position accounts for ﹤0.01% of the portfolio, ranked #1304.

Los Angeles Capital Management first reported a position in FATE in Q1 2020 and has held it in 15 quarters since. The position peaked at $2.8M in Q4 2020. 158 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Los Angeles Capital Management held 95,185 shares of Fate Therapeutics worth $114K as of Q1 2026.
  • Los Angeles Capital Management left its Fate Therapeutics share count unchanged in Q1 2026.
  • Fate Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1304 holding.
  • Los Angeles Capital Management first reported a position in Fate Therapeutics in Q1 2020 and has held it in 15 quarters since.
  • Los Angeles Capital Management's Fate Therapeutics position peaked at $2.8M in Q4 2020.
  • 158 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.